News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
IGI Laboratories, Inc. Announces the Submission of Two More ANDAs
November 21, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
BUENA, N.J.--(BUSINESS WIRE)--IGI Laboratories, Inc. (NYSE Amex: IG), a New Jersey based formulation and manufacturing company, today announced that it has submitted two more abbreviated new drug applications (ANDAs) to the US FDA.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
MORE ON THIS TOPIC
Podcast
Biogen validates anti-tau approach at AAIC, psychedelics full speed ahead, ATTR-CM shakeup
July 15, 2026
·
1 min read
·
Jef Akst
Manufacturing
Manufacturing issues prompt FDA to reject Hengrui-Elevar filings for third time
July 15, 2026
·
1 min read
·
Nick Paul Taylor
Approvals
Celcuity wins breast cancer nod, securing ‘differentiated foothold’ in market
July 15, 2026
·
2 min read
·
Tristan Manalac
Psychedelics
Final psychedelics guidance suggests FDA is ‘receptive’ to helping companies succeed
July 14, 2026
·
3 min read
·
Michael Gibney
